Figure 3.

DLL3 expression perturbs the balance between neuroendocrine and non-neuroendocrine cells in a mouse model of SCLC

(A) Schematic representation of the Cre-inducible Dll3 allele and the genetically engineered mouse model of SCLC.

(B) Representative hematoxylin and eosin (H&E) staining of sections from RPR2;R26^Luc and RPR2;R26^Dll3mutant lungs (top, scale bar 1 mm) and lung tumors (bottom, scale bar 100 μm) 6 months after tumor initiation (n ≥ 6 mice).

(C) Representative flow cytometry analysis of DLL3 cell surface expression in SCLC cells from RPR2;R26^Luc and RPR2;R26^Dll3mutant mice 5.5 months after tumor initiation.

(D) Quantification of (C) (n = 5 independent experiments).

(E) As in (C) with RPR2;R26^Luc SCLC cells differentiated by NCAM and ICAM expression.

(F) Quantification of (E) (n = 6 independent experiments).

(G) Representative flow cytometry dot plots of control cancer cells from RPR2;R26^Luc tumors with no stain, stained cells from RPR2;R26^Luc tumors, and stained cells from RPR2;R26^Dll3 tumors (from left to right).

(H–J) Quantification of NCAM^high ICAM^low, NCAM^low ICAM^high, and NCAM^low ICAM^low populations in (G).

Unpaired t-test, data represented as mean ± s.d. ∗p<0.05, ∗∗p<0.01, ∗∗∗p<0.001. See also Figure S3.